Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

1.

When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation.

Djulbegovic B, van den Ende J, Hamm RM, Mayrhofer T, Hozo I, Pauker SG; the International Threshold Working Group (ITWG).

Eur J Clin Invest. 2015 Feb 12. doi: 10.1111/eci.12421. [Epub ahead of print]

PMID:
25675907
2.

Modern health care as a game theory problem: reply.

Djulbegovic B, Hozo I, Ioannidis J.

Eur J Clin Invest. 2015 Apr;45(4):443. doi: 10.1111/eci.12414. No abstract available.

PMID:
25630659
3.

Modern health care as a game theory problem.

Djulbegovic B, Hozo I, Ioannidis JP.

Eur J Clin Invest. 2015 Jan;45(1):1-12. doi: 10.1111/eci.12380. No abstract available.

PMID:
25413314
4.

Effect of initial conditions on reproducibility of scientific research.

Djulbegovic B, Hozo I.

Acta Inform Med. 2014 Jun;22(3):156-9. doi: 10.5455/aim.2014.22.156-159. Epub 2014 Jun 15.

5.

Uncertainty about effects is a key factor influencing institutional review boards' approval of clinical studies.

Wao H, Mhaskar R, Kumar A, Miladinovic B, Guterbock T, Hozo I, Djulbegovic B.

Ann Epidemiol. 2014 Oct;24(10):734-40. doi: 10.1016/j.annepidem.2014.06.100. Epub 2014 Jul 10. Erratum in: Ann Epidemiol. 2015 Feb;25(2):144.

PMID:
25108689
6.

When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.

Cucchetti A, Djulbegovic B, Tsalatsanis A, Vitale A, Hozo I, Piscaglia F, Cescon M, Ercolani G, Tuci F, Cillo U, Pinna AD.

Hepatology. 2015 Mar;61(3):905-14. doi: 10.1002/hep.27321. Epub 2015 Jan 23.

PMID:
25048515
7.

Peptidoglycan recognition proteins kill bacteria by inducing oxidative, thiol, and metal stress.

Kashyap DR, Rompca A, Gaballa A, Helmann JD, Chan J, Chang CJ, Hozo I, Gupta D, Dziarski R.

PLoS Pathog. 2014 Jul 17;10(7):e1004280. doi: 10.1371/journal.ppat.1004280. eCollection 2014 Jul.

8.

How do physicians decide to treat: an empirical evaluation of the threshold model.

Djulbegovic B, Elqayam S, Reljic T, Hozo I, Miladinovic B, Tsalatsanis A, Kumar A, Beckstead J, Taylor S, Cannon-Bowers J.

BMC Med Inform Decis Mak. 2014 Jun 5;14:47. doi: 10.1186/1472-6947-14-47.

9.

Study design and the drug development process--reply.

Ioannidis JP, Hozo I, Djulbegovic B.

JAMA. 2014 May 21;311(19):2023-4. doi: 10.1001/jama.2014.3829. No abstract available.

PMID:
24846045
10.

Evaluation of Physicians' Cognitive Styles.

Djulbegovic B, Beckstead JW, Elqayam S, Reljic T, Hozo I, Kumar A, Cannon-Bowers J, Taylor S, Tsalatsanis A, Turner B, Paidas C.

Med Decis Making. 2014 Apr 10;34(5):627-637. [Epub ahead of print]

PMID:
24722474
11.

Improving the drug development process: more not less randomized trials.

Djulbegovic B, Hozo I, Ioannidis JP.

JAMA. 2014 Jan 22-29;311(4):355-6. doi: 10.1001/jama.2013.283742. No abstract available.

PMID:
24449311
12.

Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention.

Tesanović S, Radman M, Tesanović D, Erzen DJ, Hozo I.

Coll Antropol. 2013 Jun;37(2):367-71.

PMID:
23940976
13.

Genetic Association of Peptidoglycan Recognition Protein Variants with Inflammatory Bowel Disease.

Zulfiqar F, Hozo I, Rangarajan S, Mariuzza RA, Dziarski R, Gupta D.

PLoS One. 2013 Jun 19;8(6):e67393. Print 2013.

14.

Optimal type I and type II error pairs when the available sample size is fixed.

Ioannidis JP, Hozo I, Djulbegovic B.

J Clin Epidemiol. 2013 Aug;66(8):903-910.e2. doi: 10.1016/j.jclinepi.2013.03.002. Epub 2013 May 9.

PMID:
23664493
15.

Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials.

Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM.

PLoS One. 2013;8(3):e58711. doi: 10.1371/journal.pone.0058711. Epub 2013 Mar 21.

16.

Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error.

Miladinovic B, Mhaskar R, Hozo I, Kumar A, Mahony H, Djulbegovic B.

J Clin Epidemiol. 2013 Jun;66(6):654-9. doi: 10.1016/j.jclinepi.2012.11.007. Epub 2013 Feb 8.

PMID:
23403248
17.

The metabolic syndrome is associated with high-normal urinary albumin excretion and retinopathy in normoalbuminuric type 1 diabetic patients.

Duvnjak L, Kokić V, Bulum T, Kokić S, Krnić M, Hozo IS.

Coll Antropol. 2012 Dec;36(4):1373-8.

PMID:
23390836
18.

Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials.

Miladinovic B, Kumar A, Hozo I, Mahony H, Djulbegovic B.

Contemp Clin Trials. 2013 Mar;34(2):257-61. doi: 10.1016/j.cct.2012.12.006. Epub 2012 Dec 28.

PMID:
23274403
19.

Dual processing model of medical decision-making.

Djulbegovic B, Hozo I, Beckstead J, Tsalatsanis A, Pauker SG.

BMC Med Inform Decis Mak. 2012 Sep 3;12:94. doi: 10.1186/1472-6947-12-94.

20.

When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt.

Djulbegovic B, Hozo I.

BMC Med Res Methodol. 2012 Jun 22;12:85. doi: 10.1186/1471-2288-12-85.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk